Will Robberts

Will Robberts has extensive experience in finance and leadership roles within the biotechnology and oncology sectors. Currently serving as Chief Financial Officer at Enable Biosciences, Will has been with the company since May 2019 and became CFO in April 2024. Additionally, Will is a Board Advisor at Exsegen Genomics since January 2023 and co-founded LIPAC Oncology, where leadership roles included President and CFO until December 2023. Will also co-founded TesoRx Pharma, LLC, acting as President and CFO until the end of 2023, and previously held key executive positions at Esquire Deposition Solutions, Thomson Reuters, and LiveNote Inc. Will's career began at KPMG, leading audit and corporate finance teams, and is supported by advanced degrees in financial management from the University of Johannesburg and qualifications as a Chartered Accountant.